Table 1.
BGM no. | Gene | Inheritance | Diagnosis/novel or known syndrome, if known–phenotype exp.? | Prior genetic testing | Sequencing strategy | Solution strategy | Case source | Ref. or status |
---|---|---|---|---|---|---|---|---|
1 | CHST11 | AR | Skeletal malformation, malignant lymphoproliferative disease/novel | MA, K | Pbd WGS; S | CS | BWH, genetics | 31 |
2 | WISP3 | AR (cons.) | Prog. pseudorheumatoid arthropathy, childhood (PPAC)/ OMIM 208230 | Unknown | Pbd WGS; S | CS | BWH, Rheum | 30 |
3 | LOX | AD | Thoracic aortic aneurysm and dissection (TAAD)/novel | Panel | Pbd, c WGS; S | CC, MC, MO | BWH, Cardio | 29 |
4 | DOCK8 | AR (cons.) | Infantile inflammatory bowel disease/novel | WES | Pbd WES re-anly | CC | BCH, GI | In prep. |
5 | C3 | AD | Lower extremity ischemia/novel | None | Pbd, c WGS, S | CS, MC, FE | BWH, Rheum | In prep. |
6 | MVK | AR | Infantile-onset Crohn’s disease | None | Pbd, M WES | CC BCH, GI | In prep. | |
7 | PIEZO2 | AD (de novo) | Distal arthrogryposis type 5/gene discovery for OMIM 108145 | None | Trio WGS | CC, MC, FE | BWH, genetics | 23 |
8 | TRPM4 | AD | Right-sided structural heart defects and conduction defects | None | WES Pbd, c, M, F | CC | BCH, genetics | 38 |
9 | OBSCN/TTN a | AR | Nemaline myopathy | None | Trio WES | CC | BCH, genetics | 38 |
10 | TTN / GJB2 a | AR | Centronuclear myopathy and bilateral sensorineural hearing loss | None | Trio WES | CC | BCH, genetics | 38 |
11 | CTLA4 | AD | Multisystem autoimmune disorder/novel | WES | WES s, M, 2F | CC | BWH, GI | 39 |
12 | CAPZB | AD (de novo) | Craniofacial anomalies and hypotonia/novel | K | Pbd WGS | CC, MO | FB/DGAP | 40 |
13 | RSPRY1 | AR (cons.) | Progressive spondyloepimetaphyseal dysplasia and intel. disability/novel | None | Pbd WES | CC, MC, MO | FB/KFSH | 41 |
14 | MAP3K7 | AD (de novo) | Global developmental delay and dysmorphic facies | WES | Trio WGS | CS, MC | FB/FCC | 42, 43 |
15 | F12 | AD | Angioedema type 3/OMIM 610618 | None | Pbd WGS | CC | BWH, Allergy & Imm. | 42 |
16 | POLR1A | AD (de novo) | Acrofronto-facionasal dysostosis/OMIM 616462 | None | Trio WES | CS | FB/CHLA | d |
17 | NFIX | AD (de novo) | Marshall–Smith syndrome+glioma/OMIM 602535+Pheno. exp. | None | Trio WES | CS | FB/CHLA | d |
18 | FBN2 | AD (de novo) | Congenital contractural arachnodactyly/OMIM 121050 | None | Trio WES | CS | FB/CHLA | d |
19 | DCHS1 | AR | Van Maldergem syndrome 1 / OMIM 601390+Phen Exp. | K, Panel | Trio WES | CS | FB/BCH | d |
20 | ALX1 | AR | Frontonasal dysplasia-microphthalmia-facial clefting/OMIM 613456 | None | Trio WES | CS | FB/MGH | In prep. |
21 | CDH1 | AD | Blepharocheilodontic Syndrome 1/OMIM 119580 | None | Pbd, M WES | CC, MC | FB/CHLA | d |
22 | CNTNAP1 | AR | Lethal congenital contracture syndrome 7/OMIM 616286 | MA | Quad WES | CC | HUDN/MGH | FE |
23 | MAGEL2 | AD (de novo) | Schaaf–Yang syndrome/OMIM 614547 | MA, K | Trio WES | CS | HUDN/BCH | Closed |
24 | PAX6 b | AD (de novo) | Aniridia plus clubfoot, craniofacial disorder/OMIM 106210+Pheno. exp. | Micro | Trio WES | CS | FB/CHLA | d |
25 | EPCAM | AR | Pancreatic insufficiency, global developmental delay/OMIM 613217 | Panel | Trio WES | CS | HUDN/BCH | Closed |
26 | SNTA1 | AD | Isolated hypoparathyroidism/novel | None | Pbd, c WES | CS | MGH/Endocrin | FE |
27 | TRPV4 | AR | Distal hereditary motor neuropathy/OMIM 606071+Pheno. Exp. | None | Trio WES | CC | BCH/MCODR | FE |
28 | ITGB2 c | AD | Purpura fulminans/novel | None | Cohort WES | CS, MC, FE | UIHC | FE |
29 | MED12 b | XLR | Congenital anomalies, polydactyly/some similarity to OMIM 300895 | MA, FISH | Trio WGS | CS | HUDN/BCH | FE |
30 | MED13L | AD (de novo) | Pierre Robin syndrome, ASD/OMIM 616789 | MA, FISH, K | Trio WES | CS | FB/UCSF | https://www.facebase.org/ d |
Note that for HUDN cases, only cases solved independently by BGM are listed. Mutational data and case details are available upon request
AR autosomal recessive, AD autosomal dominant, cons consanguineous pedigree, MA microarray, K karyotype, Panel gene panel and/or individual gene tests, FISH fluorescence in situ hybridization, WES whole-exome sequencing, WGS whole-genome sequencing, Pbd proband, c cousin(s), s sib(s), re-anly re-analysis, M mother, F father, S segregation analysis, Trio proband M, F, CS crowdsourcing, CC case champion, MC multiple cases, MO model organism, FE functional experiments (completed or ongoing), BWH Brigham and Women’s Hospital, BCH Boston Children’s Hospital, MGH Massachusetts General Hospital, DGAP Developmental Genome Anatomy Project, FB NIDCR FaceBase Consortium, KFSH King Faisal Specialist Hospital and Research Center, FCC Feingold Center for Children, CHLA Children’s Hospital Los Angeles, HUDN Harvard Undiagnosed Disease Network-Clinical Site, UIHC University of Iowa Hospitals and Clinics, UHF University of Florida Health, MCODR Manton Center for Orphan Disease Research, Rheum rheumatology, Cardio cardiovascular medicine, GI gastroenterology, Allergy & Imm allergy and immunology, Endocrin endocrinology
aPossible digenic inheritance, based on phenotype
bMay not explain entire phenotype
cPotential synthetic enhancement of phenotype due to genetic interaction with additional loci within in the same functional pathway
dDe-identified genomic sequences and clinical data available via the NIDCR FaceBase Hub website (https://www.facebase.org/) contingent upon approval